We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.00 | -0.13% | 1,581.50 | 1,581.00 | 1,581.50 | 1,583.50 | 1,575.00 | 1,579.50 | 580,729 | 10:40:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.17 | 64.91B |
From Apr 2019 to Apr 2024
By Maria Armental
GlaxoSmithKline PLC's Nucala therapy has been approved to treat patients with severe asthma attacks in combination with other drugs, the Food and Drug Administration said Wednesday.
Mepolizumab, commercialized as Nucala, is an injection administered once every four weeks that is approved as an add-on maintenance treatment for patients aged 12 and older.
In controlled trials, patients who received Nucala had fewer asthma attacks that required hospitalization or emergency-room visits and reported longer breaks between asthma attacks.
The most common reported side effects included redness, swelling and itching in the injection area, back pain and fatigue. Herpes zoster infections, the virus that causes shingles, were also reported in the clinical trials. The company said patients should consider a varicella vaccination, if medically appropriate, before starting therapy with Nucala.
Shares, down 0.33% this year, edged up 0.54% to $42.83 in late trading.
Write to Maria Armental at maria.armental@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 04, 2015 19:07 ET (00:07 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
